Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

G1 Therapeutics Inc (GTHX)

NASDAQ
Currency in USD
Disclaimer
4.110
-0.065(-1.56%)
Real-time Data

GTHX Comments

junk
Anyone still holding?
So someone is pumping up again. Well, wish I had invested at 4 USD. It still can climb... but risky enough
When the rocket? :)
The price will rise to $ 45-55 in May!
wich year?
which year?
With j-code in effect and resounding approval of prescribers looking for revenue of $5.5m minimum on Cosela sales alone
Bought for 15.0In case of fail, money will help sbdy )
12 next
Bravo! Midved show time shishka! 👍
G1 Therapeutics Cosela is FDA approved drug. One course cost 34 000$ and current target audince is more than 30 000 patients per year. Given near 80% margin it results in potential operationg profit per year of more than 800 mln (34k x 30k x 0,8). But with further FDA approvals for another cancer types target audience will be more than 400k patients. So, you can recalculate potential profitability.Main reason why i'm writing this is that current capitalisation is near 900mln. Analysts target prices are 2,5-4x from current price, but I think that it is much more undervalued and at least 6-7x rise will just give reasonable price to this company. What do you think of this?
expecting 4-5m in revenue Q3 depending on delta variant with respect to sales face time. exceedingly more after permenant j-code takes effect in oct.
Fasten your seatbelts!
19.5 next week
No timka, no!
ne armageddon' tut
3x this year 🚀
why?
Look at the addressable market size for Cosela
COSELA Added to Both the NCCN Treatment Guidelines for Small Cell Lung Cancer and the NCCN Supportive Care Guidelines for Hematopoietic Growth Factors 👍👍👍
Cosela is now commercialized!!
Market is irrational...
G1 Therapeutics and Boehringer Ingelheim announce commercial availability of COSELA, the Only FDA-approved
earning date today?
Announced durung the after hours
it is raising
Patience will pay off https://shortsqueeze.com/?symbol=Gthx&submit=Short+Quote™
I will hold till 70 Medium 35
anyone know why it came down so much from premarket highs of +40%? Now it's only up 5% in regular hours
Why is it garbage? Didn't they just get FDA approval for their drug?
There is too many shorts now that why its going now dont worry just hold until next week everyone sold today will regret it Will go up again 60+ This cure will make big profits for the company
Forecast $78 https://www.tipranks.com/stocks/gthx/forecast
Blast off! 🚀
just received FDA approval!
FDA Approved G1 Therapeutics gets FDA approval of Cosela for patients with small cell lung cancer to protect bone marrow function.
SEC Form SC 13G just filed
what's it ?
🚀
Fda catalyst expected Feb 15,2021. Lets go $78!!!
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.